bioAffinity Technologies, a San Antonio-based company advancing early-stage cancer diagnostics and precision therapeutics, raised more than $4m in Series A funding.
The backers were not disclosed.
The company intends to use the funds for commercialization and further development of additional cancer tests and novel therapeutics.
Led by President and CEO Maria Zannes, bioAffinity Technologies is commercializing a non-invasive, early-stage lung cancer test called CyPath® Lung that detects the disease when it can be successfully treated. CyPath® is a platform technology that will be expanded beyond lung cancer to diagnose multiple cancers, including prostate and cervical. OncoSelect Therapeutics, the Company’s drug development division, focuses on commercialization of targeted therapies to treat cancer.